Hirulog thrombin inhibitor data

BGEN (Cambridge, Mass.) presented results of two Phase II trials, totalling 4,088 evaluable patients, showing the agent to be safer than heparin but not much

Read the full 253 word article

How to gain access

Continue reading with a
two-week free trial.